Evaluation of anticoagulation and nonsurgical major bleeding in recipients of continuous‐flow left ventricular assist devices

Continuous‐flow left ventricular assist device (LVAD) placement has become a standard of care in advanced heart failure treatment. Bleeding is the most frequently reported adverse event after LVAD implantation and may be increased by antithrombotic agents used for prevention of pump thrombosis. This...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Artificial organs Ročník 43; číslo 8; s. 736 - 744
Hlavní autori: Veasey, Tara M., Floroff, Catherine K., Strout, Sara E., McElray, Krista L., Brisco‐Bacik, Meredith A., Cook, Jennifer L., Toole, John M., Craig, Michael L., Van Bakel, Adrian B., Meadows, Holly B., Uber, Walter E.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Wiley Subscription Services, Inc 01.08.2019
Predmet:
Aged
Anticoagulants
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
anticoagulation
Bleeding
Blood Coagulation - drug effects
Congestive heart failure
Erythrocytes
Female
Heart
Heart-Assist Devices - adverse effects
Hemoglobin
Hemorrhage
Hemorrhage - etiology
Hemorrhage - therapy
Humans
Implantation
Incidence
Intracranial Hemorrhages - etiology
Intracranial Hemorrhages - therapy
left ventricular assist device
LVAD
Male
Middle Aged
Renal function
Retrospective Studies
Thromboembolism
Thrombosis
Thrombosis - prevention & control
Ventricle
Ventricular assist devices
bleeding
left ventricular assist device
LVAD
anticoagulation
ISSN:0160-564X, 1525-1594, 1525-1594
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Continuous‐flow left ventricular assist device (LVAD) placement has become a standard of care in advanced heart failure treatment. Bleeding is the most frequently reported adverse event after LVAD implantation and may be increased by antithrombotic agents used for prevention of pump thrombosis. This retrospective cohort included 85 adult patients implanted with a Heartmate II LVAD. Major bleeding was defined as occurring >7 days after implant and included intracranial hemorrhage, events requiring 2 units of packed red blood cells within a 24‐h period, and death from bleeding. Primary outcome was intensity of anticoagulation between patients with or without at least one incidence of nonsurgical major bleeding. Major bleeding occurred in 35 (41%) patients with 0.48 events per patient year and a median (IQR) time to first bleed of 134.5 (39.3, 368.5) days. The median (IQR) INR at time of bleed was 1.7 (1.4, 2.5). Median INR during follow‐up did not differ between groups and patients with major bleeding were not more likely to have a supra‐therapeutic INR. Patients who bled were more likely to have received LVAD for destination therapy, to have lower weight, worse renal function, and lower hemoglobin at baseline. Duration of LVAD support and survival were similar between groups with no difference in occurrence of thrombosis. Incidence of nonsurgical major bleeding was not significantly associated with degree of anticoagulation. Certain baseline characteristics may be more important than anticoagulation intensity to identify patients at risk for bleeding after LVAD implant. Modification of anticoagulation alone is not a sufficient management strategy and early intervention may be required to mitigate bleeding impact.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0160-564X
1525-1594
1525-1594
DOI:10.1111/aor.13456